

1 Title page

2 Full Title: Specialty palliative care use among cancer patients: A population-based study

3 Short Title: Prevalence of specialty palliative care

4 Authors: J. Brian Cassel, Donna McClish, David Buxton, Leanne Yanni, Seth Roberts, Nevena
5 Skoro, Peter May, Egidio Del Fabbro, Danielle Noreika

6

7 J. Brian Cassel, PhD, Department of Internal Medicine, Virginia Commonwealth University School of
8 Medicine

9 Donna McClish, PhD, Department of Biostatistics, Virginia Commonwealth University School of Medicine
10 (retired)

11 David Buxton, MD, Department of Supportive Care Medicine, Moffitt Cancer Center

12 Leanne Yanni, MD MBA, Bon Secours Mercy Health

13 Seth Roberts, MD PhD, MITRE

14 Nevena Skoro, MPH, Massey Comprehensive Cancer Center, Virginia Commonwealth University

15 Peter May, PhD, Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College
16 London

17 Egidio Del Fabbro, MD, Palliative Medicine Division, Medical College of Georgia, August University

18 Danielle Noreika, MD, Department of Internal Medicine, Virginia Commonwealth University School of
19 Medicine (deceased)

20

21 Corresponding Author:

22 J. Brian Cassel, PhD

23 Department of Internal Medicine

24 Virginia Commonwealth University School of Medicine

25 1101 E. Marshall Street, Suite 6030, Box 980230

26 Richmond, Virginia, USA 23298-0230

27 1-804-628-1926

28 Brian.cassel@vcuhealth.org

29

30 Key words

31 Palliative care, cancer, prevalence, equity

32

33 Running head: Palliative care use among cancer patients

34 Abstract

35 *Background.* Rigorous population-based assessments of the use of specialty palliative care (SPC) in the
36 US are rare. *Settings/subjects.* This study examined SPC use among cancer patients in a mid-sized
37 metropolitan area in Southeast US. *Measurements.* In this cancer decedent cohort study, data were
38 acquired and linked from the state-wide cancer registry; state-wide hospital discharge dataset; and local
39 SPC providers. *Results.* 12,030 individuals with cancer were included in this study; only 2,958 (24.6%)
40 used SPC. Of the 9,072 persons who did not use SPC, 3,877 (42.7%) went only to hospitals that did not
41 offer SPC; and 3,517 (38.8%) went to hospitals that offered SPC but did not use it. About half of SPC
42 recipients (1493; 50.5%) first received SPC in the final 30 days of life, including 768 (26.0%) in the final
43 week of life. Characteristics associated with using SPC use included being in an socio-economic status
44 quintile other than the lowest; being younger; being Black; having a solid (versus hematological) cancer;
45 having a shorter survival with cancer; dying in the latter two years of the study; being from an area of
46 low or complete rurality; having a hospital admission in the final 60 days prior to initiation of PC or
47 death; having more days in hospital; and living within 15 miles of a hospital offering SPC. *Conclusions:* In
48 this population-based study, only one-quarter of cancer patients used SPC, and for half who did so, it
49 came in the final 30 days of life.

50

51 Key Message

52 This novel population-based study found that about 25% of cancer patients who died 2012-2015 had
53 used of specialty palliative care (SPC). Half of them first received SPC in the final month of life.
54 Characteristics associated with SPC included being Black, younger, and residing within 15 miles of a
55 hospital offering SPC.

56 Introduction

57 Background

58 American Society of Clinical Oncology (ASCO) guidelines recommend the integration of specialist
59 palliative care (SPC) into oncology care(1). Reviews of randomized trials found that SPC improves patient
60 and family experience, including symptom burden and psychological distress, and increased probability
61 of death in preferred place(2,3).

62 While SPC capacity has increased substantially over the last two decades in the US(4–7) and
63 internationally(8,9), most people with palliative care needs do not receive SPC(10,11). In some cases
64 this may reflect patient preferences(12), but other key determinants include insufficient PC capacity,
65 sub-optimal referral rates among oncologists and low awareness of PC among patients(13–15). There
66 are potential inequities in access to scarce SPC capacity, including by diagnosis, race and ethnicity,
67 socioeconomic position, and urban and rural locations(16–18).

68 There is a need for better evidence to understand health disparities US(19,20). Robust data on how
69 many people with cancer in the US receive SPC, and the characteristics and representativeness of that
70 population, are rare for several reasons. First, people with cancer receive care across different settings
71 without routine data linkage(10). Second, it is often difficult to determine which people actually
72 received care from palliative care specialists using a single source of secondary data(21).

73 Rationale and aims

74 In the context of these evidence needs and data challenges, we compiled a population-representative
75 dataset to understand SPC engagement among people with cancer in the Richmond-Petersburg
76 metropolitan statistical area (Richmond MSA) in Virginia for 2010-2015. Our specific research questions

77 were: (1) what proportion of people with cancer in the Richmond MSA used SPC? (2) What socio-
 78 demographic and clinical characteristics were associated with SPC receipt?

79 **Methods**

80 This was a population-based decedent cohort study using secondary data. Data sources were the
 81 statewide cancer registry; statewide hospital discharge data; and medical groups' specialty palliative
 82 care encounters. The Richmond MSA includes 14 cities and counties and had 1.3 million people at the
 83 time of the study(22). The population characteristics of the population in 2011-2015(23) are shown in
 84 Table 1 for the Richmond MSA and the nation. Richmond MSA characteristics are similar to the nation,
 85 though with greater percentage of Black persons, greater percentage of English-only speakers, and
 86 higher cancer mortality-incidence rate.

87 *Table 1- Richmond MSA and national population characteristics 2011-2015*

Demographic, social, and economic characteristics	Richmond MSA Measure and margin of error	National Measure and margin of error
Age		
18 years and over	77.5% (0.1%)	78.3% (0.1%)
65 years and over	13.3% (0.1%)	17.7% (0.1%)
Race		
White (only)	61.9% (0.1%)	60.5% (0.1%)
Black / African American (only)	30.0% (0.1%)	12.1% (0.1%)
American Indian (only)	0.4% (0.1%)	1.0% (0.1%)
Asian (only)	3.6% (0.1%)	6.0% (0.1%)
Native Hawaiian / other Pacific Islander (only)	0.0% (0.1%)	0.2% (0.1%)
Other race (only)	1.4% (0.1%)	7.4% (0.1%)
Two or more races	2.6% (0.1%)	12.8% (0.1%)
Hispanic or Latino (of any race)	5.5% (0.1%)	19.4% (0.1%)
Education		
<9 th grade	4.3% (0.2%)	4.6% (0.1%)

Demographic, social, and economic characteristics	Richmond MSA Measure and margin of error	National Measure and margin of error
9-12 th grade no diploma	7.6% (0.2%)	5.6% (0.1%)
High school graduate including equivalency	26.4% (0.4%)	25.9% (0.1%)
Some college, no degree	21.1% (0.4%)	18.9% (0.1%)
Associate’s degree	6.9% (0.2%)	8.8% (0.1%)
Bachelor’s degree	21.1% (0.3%)	21.8% (0.1%)
Graduate or professional degree	12.6% (0.2%)	14.3% (0.1%)
Language spoken at home		
English only	90.1% (0.2%)	77.5% (0.1%)
Language other than English	9.9% (0.2%)	22.5% (0.1%)
Speak English less than “very well”	3.9% (0.1%)	8.7% (0.1%)
Economic characteristics		
Unemployment rate in civilian labor force	7.5% (0.3%)	4.3% (0.1%)
Median household income	\$59,919 (\$647)	\$77,719 (\$186)
With food stamp /SNAP benefits past 12 months	10.8% (0.3%)	12.2% (0.1%)
Families with income in past 12 months below poverty level	8.8% (0.3%)	8.8% (0.1%)
Cancer mortality-incidence age-adjusted rate (per 100,000)	463.16	449.21

88

89 Sources: US Census American Community Survey data(23); US Centers for Disease Control WONDER(24).

90

91 Data Sources

92 The Virginia Cancer Registry (VCR) provided statewide data on May 7, 2018 on adult cancer decedents

93 (>= 21 at time of death) who died 2012-2015. Data elements from the VCR included patient-level

94 identifiers and demographics; and tumor-level diagnosis dates, cancer types, histology, stage at

95 diagnosis, and locality of residence (including census tract) at time of diagnosis.

96 Virginia Health Information (VHI) provided statewide data on all hospitalizations from 2010-2015 for
97 those cancer decedents on September 12, 2019. Data elements included admission and discharge dates,
98 diagnoses, procedures, charges, insurance type, and hospital identifiers.

99 The three palliative care programs provided patient-level data on SPC services from 2010-2015 in
100 December 2019. Data elements included patient identifiers and dates of services.


101 Authors representing the three palliative care providers (D. Buxton, D. Noreika, E. Del Fabbro, L. Yanni,
102 S. Roberts had access to patient identifiers only for their own programs prior to submitting their data.

103 One author (N. Skoro) had access to patient identifiers in the data from the cancer registry and palliative
104 care provider groups; the data were de-identified prior to further analysis.

105 Availability of SPC

106 Information about availability of SPC services was obtained directly from the SPC programs. Within the
107 Richmond MSA, there were 3 distinct medical groups providing SPC services at 6 hospitals. One was an
108 academic medical center providing hospital-PC and clinic-PC; a second group was at Catholic, non-profit
109 system with four hospital locations offering hospital-PC, office-PC and home-PC; and a third group was
110 at a for-profit hospital. All three programs had multi-disciplinary teams; two were certified by the Joint
111 Commission's hospital-PC certification program(25). These were the only SPC providers in the Richmond
112 MSA in the study time period. Emails, websites, and phone calls confirmed that other hospitals within or
113 nearby the area did not have SPC services during the years of interest (2010-2015), and that no other
114 medical groups or insurance-based providers were operating in the region during that time. The two
115 three hospitals that did not offer SPC were for-profit. None of the 5 small, rural hospitals just outside of
116 the MSA offered palliative care services at that time. See Figure 1.

117 *Figure 1 - Availability of Specialist Palliative Care within and around the Richmond MSA*



118
119 *Hospitals within and near the Richmond-Petersburg Metropolitan Statistical Area. Locations are approximate. Map*
120 *source: Richmond Times Dispatch(26). Hospital location source: Virginia Hospital & Health System Association(27).*
121 *SPC = specialty palliative care.*

122
123 Data linkage. VCR data were linked to hospitalization data by VHI using hashed (encrypted) social
124 security numbers (SSN). VCR data were linked by the researchers to SPC data using patient name and
125 date of birth. The resulting VCR-VHI-SPC dataset was then linked to US census data based on census
126 tract identifiers at the time of diagnosis.

127 Inclusion and Exclusion Criteria. VCR data included cancer registry cases (primary malignant neoplasms)
128 for people who were at least 21 years old at the time of diagnosis and were known to have died
129 between 2012-2015. VCR excluded cases that were diagnosed or treated within the Veterans Health
130 Administration system per VCR requirements, and we further excluded people whose only cancer was a

131 non-melanoma skin cancer. Using the combined VCR-VHI data, we included people that were living
132 within the Richmond MSA at the time of cancer diagnosis, and excluded cases that had additional
133 cancers diagnosed outside the MSA. We excluded cases that had hospitalizations outside of the
134 Richmond MSA (beyond the several small, rural hospitals just outside the MSA, none of which had SPC
135 services) because we had palliative care data only from providers within the MSA.

136 In the dataset provided by the VCR there were 13,260 adult cancer decedents who died at age 21+ in
137 years 2012-2015 who were living in the Richmond MSA at the time cancer diagnosis. We excluded 1,230
138 people because they either did not have a valid SSN (n=91) which would have prevented linking them to
139 VHI hospitalization data; or had hospitalizations beyond the 13 hospitals within or nearby the Richmond
140 MSA within 2 years of death (n=792) which would have prevented our assessment of their PC access or
141 exposure; or had irreconcilable dates from multiple data sources (n=377) such as admission, discharge
142 dates or initial PC dates after date of death, or incomplete diagnosis dates. The remaining dataset
143 contained 12,030 cancer decedents.

144 Variables used in this study. For each patient, the data included at least two years of potential
145 hospitalizations and SPC encounters prior to death. Because we were examining factors related to
146 receiving palliative care, the number of hospitalizations as a potential predictor variable was measured
147 prior to initiation of SPC if received, else prior to death.

148 For the descriptive analyses of what proportion of the cancer population used SPC, our outcome
149 variables included a binary variable of SPC use, and the timing of first SPC encounter prior to death.
150 Predictor variables included age at time of cancer diagnosis, age at time of death, sex, race, cancer type,
151 rurality, and socio-economic status (SES). A rurality index was used, based on the percent of the
152 population living in non-urban areas divided into 4 groups representing 0% rural, 1-50% rural, 51-99%
153 rural, and 100% rural(28). The socio-economic status variable was derived from 7 data elements from

154 the American Community Survey census data and converted to quintiles(29). Imputation for SES was
155 performed where only 5 or 6 of those data elements were available; quintiles were ranked from low SES
156 to high SES. Cancers were characterized in two ways: solid versus hematologic, and poor prognosis or
157 not. Cancers with poor prognosis were those that nationally had 40% or fewer surviving for 5
158 years(30,31); or had distant metastases at diagnosis.

159 Statistical analyses. Frequencies and percentages were used to describe categorical variables, with
160 means (standard deviations) and/or median (interquartile range) used for continuous variables.
161 Univariate association with SPC used Chi-square (categorical variables), or Wilcoxon Rank Sum test
162 (continuous variables). Multivariable analysis of SPC use used backward logistic regression, with
163 variables staying in the model as long as $p \leq 0.05$. Cox proportional hazards regression was used to
164 evaluate characteristics associated with timing of SPC for those who used SPC. Analyses were conducted
165 in SAS(32).

166 IRB, privacy, funding, and conflicts of interest. The Virginia Department of Health approved the study on
167 May 2, 2018 and the VCU IRB exempted this study on January 8, 2019. Data use agreements were
168 established with VCR, VHI, and the two medical groups outside of VCU. The privacy officers of each
169 medical group approved the acquisition of data on SPC use. All entities waived the need for consent as
170 this study concerned decedents. The study was funded by a pilot grant from the VCU Department of
171 Internal Medicine and a pilot grant from the American Cancer Society; neither entity had a further role
172 in the research or the reporting of results. The study authors report no conflicts of interest.

173 Results

174 Patient characteristics

175 Clinical, demographic, geographic and socio-economic characteristics of the cancer population are
176 provided in the first column of Table 2. The median distance from patient residence to nearest hospital

177 offering SPC was 5.5 miles. One-fifth (20.6%) lived in an area that was at least 51% rural. About half
 178 (55.2%) spent more than 5 days in a hospital in the last six months of life. Median age was 68 at
 179 diagnosis and 74 at death; 47.8% were female; 29.8% were Black. 11.4% had a hematologic malignancy
 180 and 40.6% had a poor prognosis cancer at time of diagnosis.

181 *Table 2 - Univariate analyses of SPC use (n=12,030)*

Characteristics	Total	Used SPC	Did not use SPC	p-value
Age at death (mean (SD), median (IQR))	73.3 (13.2) 74.0 (20.0)	69.4 (13.8) 70.0 (20.0)	74.5 (12.8) 76.0 (18.0)	<0.0001
Age at diagnosis (mean (SD), median (IQR)) *	67.9 (13.0) 68.0 (17.0)	64.6 (13.5) 65.0 (18.0)	68.9 (12.6) 69.0 (17.0)	<0.0001
Years from Diagnosis to Death (mean (SD), median (IQR)) *	5.3 (7.0) 2.0 (7.7)	4.5 (6.5) 1.4 (5.9)	5.6 (8.3) 2.2 (8.3)	0.0021
Miles to hospital offering SPC (mean(SD), median (IQR)) **	9.3 (10.8) 5.5 (11.9)	7.4 (8.0) 4.7 (8.9)	9.9 (11.5) 5.6 (14.5)	<0.0001
Hospital days 6 month prior to SPC or death (n (%))				<0.0001
0	3025	326 (11.8)	2699 (88.2)	
1-5	2368	548 (23.1)	1820 (76.9)	
>5	6637	2084 (31.4)	4553 (68.6)	
Cancer Site (first if multiple) (n (%)) *				<0.0001
Breast	1433	369 (25.7)	1064 (74.3)	
Prostate	1545	295 (19.1)	1250 (81.9)	
Lung	2533	597 (23.6)	1936 (76.4)	
Colo-rectal	1240	316 (25.5)	924 (74.5)	
Other solid	4093	1112 (27.2)	2981 (72.8)	
Hematologic	1186	269 (22.7)	917 (77.3)	
Race (n (%))				<0.0001
White	8248	1841 (22.3)	6407 (77.7)	
Black	3581	1060 (29.6)	2521 (70.4)	
Other	201	57 (28.4)	144 (71.6)	
Sex (n (%))				0.0141
Male	6279	1486 (23.7)	4893 (76.3)	
Female	5751	1472 (25.6)	4279 (74.4)	

Characteristics	Total	Used SPC	Did not use SPC	p-value
Year of Death (n (%))				<0.0001
2012	2380	535 (22.5)	1845 (77.5)	
2013	3203	701 (21.9)	2502 (78.1)	
2014	3143	784 (24.9)	2359 (75.1)	
2015	2204	938 (28.4)	2366 (71.6)	
Multiple Cancers (n (%))				0.1701
Yes	1906	475 (23.3)	1461 (76.7)	
No	10124	2483 (24.8)	7611 (75.2)	
Any hematologic cancer (n (%))				0.0734
Yes	1370	310 (22.6)	1060 (77.4)	
No	10660	2648 (24.8)	8012 (75.2)	
SES rank** (n (%))				0.6857
1 st quintile	2348	563 (24.0)	1785 (76.0)	
2 nd quintile	2390	602 (25.2)	1788 (74.8)	
3 rd quintile	2379	573 (24.1)	1806 (75.9)	
4 th quintile	2349	592 (25.2)	1757 (74.8)	
5 th quintile	2387	605 (25.3)	1782 (74.7)	
Rurality Group** (n (%))				0.0033
0% rural	7543	1854 (24.6)	5689 (75.4)	
1-50% rural	1868	482 (25.8)	1386 (74.2)	
51-99% rural	678	133 (19.6)	545 (80.4)	
100% rural	1797	476 (26.5)	1321 (73.5)	
Poor Prognosis Cancer (n (%))				0.0003
Yes	4889	1287 (26.3)	3602 (73.7)	
No	7141	1671 (23.4)	5407 (77.6)	

182

183 *SPC = specialty palliative care; SD = standard deviation; IQR = interquartile range; SES =*
 184 *socioeconomic status. *using initial cancer if patient had multiple cancers. **missing 177 for*
 185 *SES; missing 144 for rurality; missing 199 for zip code which was used for computing miles from*
 186 *hospitals offering SPC.*

187

188 Use of local hospitals

189 Hospital admission was evaluated at 24, 18 and 6 months before death. Looking at all 12,030 cancer
190 decedents and the full 24-month period, 10,273 (85.4%) went to a hospital; of them, 8,051 (78.4%) went
191 to a hospital offering SPC. In the 18 months before death, 9,914 (82.4%) had at least one hospitalization,
192 and 7,671 of them (77.4%) went to a hospital offering SPC. In the 6 months before death, 9005 (74.9%)
193 were hospitalized at least once and 6,815 of them (75.7%) went to a hospital offering SPC.

194 Some patients used more than 1 hospital. Of the 6,614 patients who had at least 1 hospitalization the 30
195 days prior to PC or death, 344 (5.2%) went to more than 1 hospital. Of the 8,301 patients who had at
196 least 1 hospitalization over the 3 months prior to PC or death, 921 (11.1)% went to more than 1 hospital.
197 Of the 9,005 patients who had at least 1 hospitalization over the 6 months prior to PC or death, 1,333
198 (14.8%) went to more than 1 hospital.

199 Use and timing of specialty palliative care

200 One-quarter of the cancer decedents (n=2,958, 24.6%) received SPC from one or more sources in the 18
201 months before death. Of the 7,671 who went to a hospital offering SPC within 18 months before death,
202 2,671 (34.8%) received SPC; of the other 4,359 who did not go to a hospital offering SPC, 287 (6.6%)
203 received SPC in clinic or home settings. While most SPC recipients (97.5%) received SPC from a single
204 medical group, 73 received SPC from two medical groups and 1 person received SPC from all 3.

205 Of the 9,072 persons who did not use palliative care, 3,877 (42.7%) went only to hospitals that did not
206 offer SPC; 3,517 (38.8%) went to hospitals that offered SPC but did not use it; and the remaining 1,678
207 (18.5%) did not go to any hospital (and did not use community-based SPC).

208 From first cancer diagnosis to first SPC encounter, a mean of 4.5 years passed (SD 6.5), with a median of
209 1.4 years (IQR 5.9). From first SPC encounter to death, the mean was 123.9 days (SD 243) with a median
210 of 30 days (IQR 107). From first SPC encounter to death, 1493 (50.5%) were in the final 30 days of life,

211 including 768 (26.0%) in the final week of life, 450 (15.2%) in the final 3 days of life, and 126 (4.3%) had a
212 first SPC encounter on the day they died.

213 Characteristics associated with SPC use and timing

214 Most of the characteristics of the population that we evaluated were significantly associated with
215 whether SPC was used, as shown in Table 2. The rate of SPC use increased over the years, from around
216 22% for those dying in 2012 or 2013, and increasing to 28% by 2015.

217 As shown in Table 3, the following characteristics were associated with using SPC in the multivariate
218 analysis: being in an SES quintile other than the lowest; being younger; being Black; having a solid
219 (versus hematological) cancer; having a shorter survival with cancer; dying in the latter two years of the
220 study; being from an area of low or complete rurality; having a hospital admission in the final 60 days
221 prior to initiation of PC or death; having more days in hospital; and living within 15 miles of a hospital
222 offering SPC. The AUC statistic was 0.749.

223 *Table 3 - Multivariate analysis of SPC use (n=11,689)*

Characteristics	OR (95% CI)
SES	
Rank 2 vs 1	1.27 (1.09, 1.49)
Rank 3 vs 1	1.30 (1.11, 1.53)
Rank 4 vs 1	1.41 (1.20, 1.66)
Rank 5 vs 1	1.53 (1.30, 1.80)
Age at death (10-year increments)	0.78 (0.75,0.80)
Black	1.37 (1.26, 1.57)
Any hematological malignancy	0.81 (0.70, 0.93)
Less than 15 miles to hospital offering SPC	2.66 (2.33, 3.04)
Years from diagnosis to death	

Characteristics	OR (95% CI)
<1 month vs >1 year	1.80 (1.58, 2.05)
1-2 months vs >1 year	1.11 (0.90, 1.36)
2-12 months vs > 1 year	0.98 (0.87, 1.10)
Death year	
2013 vs 2012	1.12 (0.98, 1.28)
2014 vs 2012	1.29 (1.13, 1.48)
2015 vs 2012	1.60 (1.40, 1.83)
Rurality group	
1-50% vs 0% rural	1.23 (1.08, 1.39)
51-99% vs 0% rural	1.02 (0.82, 1.27)
100% vs 0 % rural	1.77 (1.53,2.04)
Hospital days in 6 months prior to SPC or death	
1-5 vs 0 days	3.79 (3.18, 4.53)
>5 vs 0 days	5.81 (4.96, 6.80)

224 *SPC = specialty palliative care; SES = socioeconomic status; OR = odds ratio; CI = confidence interval.*

225

226 Two secondary regressions were performed: one model limited to patients admitted to hospitals
227 offering SPC (to control for access to SPC), and one model limited patients with poor-prognosis cancers
228 or stage (which are commonly targeted in SPC intervention studies). Similar AUCs were achieved and
229 certain variables were significant predictors across models: younger age, being Black, more recent year,
230 shorter distance to SPC hospital, rurality group, and more days in hospital in final 6 months. See
231 Supporting Information.

232 Univariate analyses and Cox proportional hazards regression were also conducted to determine
233 characteristics associated with the timing of SPC relative to death, for those who used SPC (n=2,792).

234 Few variables were statistically significant in the multivariate analysis, as shown in Table 4. The

235 characteristic associated with longest time from SPC to death was having zero hospitalizations in the six
236 months prior. A number of variables that were associated with SPC use, such as race, cancer type,
237 rurality and SES, were not significantly associated with the timeliness of SPC among those who used it.

238 *Table 4 - Characteristics associated with fewer days from SPC to death, multivariate analysis.*

Characteristics	N	Mean days	Median days	HR (95% CI)
Age				
Age <50	223	101.4	43	--
Age >50	2569	72.3	25	1.31 (1.14, 1.51)
Death year				
2012	524	54.8	19	--
2013	675	74.1	22	0.858 (0.76, 0.96)
2014	733	75.6	29	0.842 (0.75, 0.94)
2015	860	86.1	34	0.784 (0.70, 0.88)
Time from diagnosis to SPC				
0-1 month	517	58.4	16	--
1-2 months	156	68.0	27	0.86 (0.72, 1.04)
>2 months	2119	79.0	29	0.79 (0.72, 0.88)
Number of hospitalizations 6 months prior				
0	198	137.3	90	--
1	1173	79.7	28	1.44 (1.23, 1.68)
2	731	65.3	23	1.68 (1.43, 1.97)
>2	690	57.7	17	1.85 (1.57, 2.17)

239 SPC = specialty palliative care; HR = hazard ratio; CI = confidence interval.

240 Discussion

241 In this population-based study of specialty palliative care use by cancer patients in a mid-sized
242 metropolitan area in the US, only one quarter of the cancer population (24.6%) received SPC, and this
243 often came near the end of life, with 50% first receiving SPC in the final 30 days of life. There was some
244 improvement over the years of the study, with 22% of those who died in 2012 or 2013 receiving SPC,
245 25% of those of who died in 2014, and 28% of those who died in 2015.

246 By today's standards, this is suboptimal cancer care. It is unclear why SPC was "too little, too late" for
247 cancer patients. The answer does not seem to be access alone. Most (6 of 8) hospitals within the MSA
248 offered SPC. Most patients in the study (82.4%) had a hospital admission in the 18 months before death,
249 and most of those (77.4%) went to a hospital offering SPC. While distance to the closest hospital offering
250 SPC is a significant predictor of SPC use, the median distance for SPC users (7.4 miles) and non-SPC users
251 (9.9 miles) is similar.

252 One could hypothesize that the low uptake is due to the culture of cancer care and the visibility of SPC in
253 local cancer centers. At the time of the study (deaths occurred 2012-2015), the hospitals providing SPC
254 had mature programs with multi-disciplinary teams. Bakitas's "Project Enable II" trial had been
255 published in 2009(33); Temel's landmark trial had been published in 2010(34); the Joint Commission's
256 certification of hospital-PC programs was launched in 2011(25); and ASCO's provisional clinical
257 guidelines for palliative care were published in 2012(35). Yet the number of non-users of SPC who went
258 to a hospital offering SPC (3,517) was almost as large as those who went to hospitals lacking SPC (3,877).
259 Significant variation in SPC use was found; 9 variables were associated with SPC use including socio-
260 economic status; younger age; race (being Black); cancer type (solid tumors); length of survival with
261 cancer; rurality; hospital use; and shorter distance to a hospital offering SPC. Fewer variables were
262 Fewer variables were associated with the timing of SPC relative to death, among those who used SPC.
263 This points to multiple potential sources of inequity. Two noteworthy findings were that SPC use was
264 greater among younger patients and Black patients.

265 In this study, Black cancer patients were more likely to use SPC than White cancer patients, 29.6% versus
266 22.3%. This is not attributable to a difference in the hospitals they went to; of those hospitalized in the
267 last six months of life, Black patients and other patients were about equally likely (76.8% versus 75.2%)
268 to go to a hospital offering SPC. Many studies of end-of-life healthcare in the US have documented

269 lower use of hospice by Black compared to White patients; for example, 35.6% of Black Medicare
270 decedents versus 50.5% of White Medicare decedents had enrolled in hospice in 2023(36). Research on
271 race differences in non-hospice SPC is less common, and much of the research on the prevalence of SPC
272 has relied upon invalid measures of SPC use(21).

273 Other studies of palliative care prevalence for cancer patients have been conducted; their methods and
274 definitions of palliative care differ substantially. A survey-based study in Japan estimated a 24% SPC rate
275 for cancer patients(37). A study in Belgium estimated 56.4% SPC use for hematological cancers, and 73%
276 for most solid cancer types(38). Several studies in Ontario have estimated SPC prevalence and its impact
277 for cancer patients(39–42), with one finding 75.6% of hospitalized patients with terminal illnesses such
278 as cancer accessed SPC(40). Most studies in the US purporting to evaluate population-level prevalence
279 of palliative care services have serious methodological flaws(21). Two rigorous studies found lower rates
280 than the current study. Hugar et al. evaluated SPC among patients with bladder cancer 2008-2013,
281 finding that 3.6% received SPC(43); and Hua et al. evaluated patients with metastatic cancer 2017-2019,
282 finding 12.0% received SPC(44). Those two studies used national Medicare data; the current study
283 employed a geographically focused dataset inclusive of all insurance types and all ages.

284 Methodological strengths

285 The current study used population-based data sets appropriate for determining population-level use of
286 SPC. The starting place was population data in the form of the state cancer registry. This was then linked
287 to another population data source, state-wide hospital discharges. Finally, institutional data on SPC use
288 was acquired from SPC providers in the MSA.

289 This approach had several strengths. Not all patients were hospitalized, and because early palliative care
290 may reduce the need for subsequent hospitalizations(45–47), it was critical to start with all cancer
291 decedents regardless of hospital use. Second, we used statewide cancer registry and hospital discharge

292 data to exclude people who were diagnosed or hospitalized outside of the metropolitan area, thus
293 focusing the analysis on people for whom we could evaluate SPC use. Most importantly, we did not rely
294 on the ICD9/10 codes for “palliative care encounter” (V66.7 / Z51.5) which are not suitable for research
295 on SPC(21).

296 To our knowledge, this approach has not been used in prior studies of SPC in the US. It is a replicable
297 method that would work well in other small- and medium-sized metropolitan statistical areas. The
298 challenge of using this approach in larger areas would be in securing data use agreements with larger
299 numbers of SPC providers.

300 Limitations

301 This study was limited to a particular metropolitan area and findings may not be generalizable to other
302 metropolitan areas or regions. The census data in Table 1 demonstrate that the population of this
303 metropolitan area is not unusual. The study was limited to adults with cancer, and findings may not be
304 applicable to pediatric populations or other diseases. Socio-economic characteristics were measured at
305 the census tract level (not the patient level); this introduces some degree of measurement error.
306 Information on comorbidities and insurance type are available in the hospital discharge data, but the
307 analyses in this study were not limited to those who were hospitalized. It is possible that some people
308 received some healthcare outside of Virginia.

309 The study examined healthcare that occurred between 2010 and 2015, and may no longer be
310 representative of care in the region. However, informal interviews with palliative care leaders in the
311 region have indicated that the scope and volume of SPC for cancer patients remains largely the same.
312 While some time has passed since the data or phenomena, no other study in the US has been published
313 in the interim, using population-based data. Future work using similar population-based methods in
314 other metropolitan areas, in more recent years, would address some of the limitations of this study.

315 Conclusion

316 To our knowledge this is the first study in the US to combine state-wide population-level datasets with
317 local SPC encounter data from SPC providers, to produce a regional evaluation of SPC use. This
318 population-based study of specialty palliative care use among cancer patients found that 25% used SPC,
319 identified 9 variables associated with SPC use, and found that Black patients were more likely to use
320 SPC, in contrast with national data on hospice use.

321

322 References

- 323 1. Sanders JJ, Temin S, Ghoshal A, Alesi ER, Ali ZV, Chauhan C, et al. Palliative Care for Patients With
324 Cancer: ASCO Guideline Update. *J Clin Oncol*. 2024 Jul;42(19):2336–57.
- 325 2. Gomes B, N C, V C, P MP, I.j H, M B. Effectiveness and cost-effectiveness of home palliative care
326 services for adults with advanced illness and their caregivers. *Sao Paulo Med J*. 2016 Feb;134(1):93.
- 327 3. Bajwah S, Oluyase AO, Yi D, Gao W, Evans CJ, Grande G, et al. The effectiveness and
328 cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and
329 their caregivers - Bajwah, S - 2020 | Cochrane Library. [cited 2024 Oct 3]; Available from:
330 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012780.pub2/full?cookiesEnabled>
331 d
- 332 4. Rogers MM, Meier DE, Morrison RS, Moreno J, Aldridge M. Factors Associated with the Adoption
333 and Closure of Hospital Palliative Care Programs in the United States. *J Palliat Med*. 2021
334 May;24(5):712–8.
- 335 5. Calton BA, Alvarez-Perez A, Portman DG, Ramchandran KJ, Sugalski J, Rabow MW. The Current State
336 of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care
337 Survey. *J Natl Compr Canc Netw*. 2016 Jul 1;14(7):859–66.
- 338 6. Hui D, De La Rosa A, Chen J, Dibaj S, Delgado Guay M, Heung Y, et al. State of palliative care services
339 at US cancer centers: An updated national survey. *Cancer*. 2020;126(9):2013–23.
- 340 7. Rogers M, Meier DE, Morrison RS, Moreno J, Aldridge M. Hospital Characteristics Associated with
341 Palliative Care Program Prevalence. *J Palliat Med*. 2020 Oct;23(10):1296–9.
- 342 8. Arias-Casais N, Garralda E, Rhee JY. EAPC Atlas of Palliative Care in Europe 2019 [Internet].
343 Vilvoorde: EAPC Press; [cited 2024 Oct 4]. Available from: <https://hdl.handle.net/10171/56787>
- 344 9. Cicely Saunders International [Internet]. 2019 [cited 2024 Oct 4]. New Interactive Atlas of Variation
345 for Palliative and End of Life Care. Available from: <https://cicelysaundersinternational.org/new-interactive-atlas-of-variation-for-palliative-and-end-of-life-care/>
346
- 347 10. Tanuseputro P, Budhwani S, Bai YQ, Wodchis WP. Palliative care delivery across health sectors: A
348 population-level observational study. *Palliat Med*. 2017 Mar 1;31(3):247–57.
- 349 11. Axelsson B. The Challenge: Equal Availability to Palliative Care According to Individual Need
350 Regardless of Age, Diagnosis, Geographical Location, and Care Level. *Int J Environ Res Public Health*.
351 2022 Apr 1;19(7):4229.
- 352 12. Teno JM, Gozalo P. Financing the Care of the Seriously Ill—“Hell No, I Won’t Go.” *JAMA Health*
353 *Forum*. 2021 Mar 11;2(3):e210363.
- 354 13. Kamal AH, Wolf SP, Troy J, Leff V, Dahlin C, Rotella JD, et al. Policy Changes Key To Promoting
355 Sustainability And Growth Of The Specialty Palliative Care Workforce. *Health Aff (Millwood)*. 2019
356 Jun;38(6):910–8.

- 357 14. Hawley P. Barriers to Access to Palliative Care. *Palliat Care Res Treat*. 2017 Jan
358 1;10:1178224216688887.
- 359 15. Shalev A, Phongtankuel V, Kozlov E, Shen MJ, Adelman RD, Reid MC. Awareness and Misperceptions
360 of Hospice and Palliative Care: A Population-Based Survey Study. *Am J Hosp Palliat Med*. 2018 Mar
361 1;35(3):431–9.
- 362 16. Davies JM, Sleeman KE, Leniz J, Wilson R, Higginson IJ, Verne J, et al. Socioeconomic position and
363 use of healthcare in the last year of life: A systematic review and meta-analysis. *PLoS Med*. 2019 Apr
364 23;16(4):e1002782.
- 365 17. Bassah N, Beranek J, Kennedy M, Onabadejo J, Santos Salas A. Inequities in access to palliative and
366 end-of-life care in the black population in Canada: a scoping review. *Int J Equity Health*. 2024
367 Dec;23(1):1–9.
- 368 18. Niedzwiecki MJ, Forrow LV, Gellar J, Pohl RV, Chen A, Miescier L, et al. The Medicare Care Choices
369 Model was associated with reductions in disparities in the use of hospice care for Medicare
370 beneficiaries with terminal illness. *Health Serv Res*. 2024;59(4):e14289.
- 371 19. LaVeist TA, Pérez-Stable EJ, Richard P, Anderson A, Isaac LA, Santiago R, et al. The Economic Burden
372 of Racial, Ethnic, and Educational Health Inequities in the US. *JAMA*. 2023 May 16;329(19):1682–92.
- 373 20. Griggs JJ. Disparities in Palliative Care in Patients With Cancer. *J Clin Oncol*. 2020 Mar 20;38(9):974–
374 9.
- 375 21. Cassel JB. What Does “Palliative Care” Represent in Research Using Secondary Data? *J Pain*
376 *Symptom Manage*. 2024 Oct 1;68(4):421–8.
- 377 22. Bureau UC. *Census.gov*. [cited 2024 Jul 23]. *Census.gov*. Available from:
378 <https://www.census.gov/en.html>
- 379 23. US Census Bureau. *Census.gov*. [cited 2024 Oct 3]. Richmond MSA Data Profile 2011-2015. Available
380 from: <https://www.census.gov/programs-surveys/acs/>
- 381 24. United States and Puerto Rico Cancer Statistics, 1999-2015 Mortality Incidence Rate Ratios Archive
382 Results Form [Internet]. [cited 2024 Oct 28]. Available from:
383 [https://wonder.cdc.gov/controller/datarequest/D146;jsessionid=75E3D809EDFBC8CE64FB6241191](https://wonder.cdc.gov/controller/datarequest/D146;jsessionid=75E3D809EDFBC8CE64FB6241191F)
384 F
- 385 25. The Joint Commission Palliative Care Certification [Internet]. [cited 2024 Oct 3]. Available from:
386 [https://www.jointcommission.org/https://www.jointcommission.org/what-we-](https://www.jointcommission.org/https://www.jointcommission.org/what-we-offer/certification/certifications-by-setting/hospital-certifications/palliative-care-certification/)
387 [offer/certification/certifications-by-setting/hospital-certifications/palliative-care-certification/](https://www.jointcommission.org/https://www.jointcommission.org/what-we-offer/certification/certifications-by-setting/hospital-certifications/palliative-care-certification/)
- 388 26. Richmond Times-Dispatch [Internet]. 2015 [cited 2024 Jul 23]. Richmond MSA map. Available from:
389 https://richmond.com/richmond-msa-map/image_36d7c4d7-a51b-5af5-927a-6bf2f76acda9.html
- 390 27. VHHA [Internet]. [cited 2024 Jul 23]. HomePage. Available from: <https://vhha.com/>

- 391 28. Moss JL, Stinchcomb DG, Yu M. Providing Higher Resolution Indicators of Rurality in the
392 Surveillance, Epidemiology, and End Results (SEER) Database: Implications for Patient Privacy and
393 Research. *Cancer Epidemiol Biomarkers Prev*. 2019 Sep 3;28(9):1409–16.
- 394 29. Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to
395 investigate health disparities while protecting the confidentiality of cancer registry data. *Cancer*
396 *Causes Control*. 2014 Jan 1;25(1):81–92.
- 397 30. Cancer Facts and Statistics [Internet]. [cited 2024 Jul 23]. Available from:
398 <https://www.cancer.org/research/cancer-facts-statistics.html>
- 399 31. SEER [Internet]. [cited 2024 Jul 23]. Cancer Survival Statistics - SEER Cancer Statistics. Available
400 from: <https://seer.cancer.gov/statistics/types/survival.html>
- 401 32. SAS: Data and AI Solutions [Internet]. [cited 2024 Jul 23]. Available from:
402 https://www.sas.com/en_us/home.html
- 403 33. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, et al. Effects of a palliative care
404 intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II
405 randomized controlled trial. *JAMA*. 2009 Aug 19;302(7):741–9.
- 406 34. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for
407 patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010 Aug 19;363(8):733–42.
- 408 35. Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of Clinical
409 Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology
410 Care. *J Clin Oncol*. 2012 Mar 10;30(8):880–7.
- 411 36. Wondafrash M. 2023 NHPCO Facts and Figures Report Now Available [Internet]. NHPCO. 2023 [cited
412 2024 Jul 23]. Available from: [https://www.nhpc.org/wp-content/uploads/NHPCO-Facts-Figures-](https://www.nhpc.org/wp-content/uploads/NHPCO-Facts-Figures-2023.pdf)
413 [2023.pdf](https://www.nhpc.org/wp-content/uploads/NHPCO-Facts-Figures-2023.pdf)
- 414 37. Kizawa Y, Morita T, Hamano J, Nagaoka H, Miyashita M, Tsuneto S. Specialized Palliative Care
415 Services in Japan: A Nationwide Survey of Resources and Utilization by Patients With Cancer. *Am J*
416 *Hosp Palliat Med*. 2013 Sep 1;30(6):552–5.
- 417 38. Vanbutsele G, Deliens L, Cocquyt V, Cohen J, Pardon K, Chambaere K. Use and timing of referral to
418 specialized palliative care services for people with cancer: A mortality follow-back study among
419 treating physicians in Belgium. *PLOS ONE*. 2019 Jan 17;14(1):e0210056.
- 420 39. Seow H, Barbera LC, McGrail K, Burge F, Guthrie DM, Lawson B, et al. Effect of Early Palliative Care
421 on End-of-Life Health Care Costs: A Population-Based, Propensity Score–Matched Cohort Study. *JCO*
422 *Oncol Pract*. 2022 Jan;18(1):e183–92.
- 423 40. Seow H, O’Leary E, Perez R, Tanuseputro P. Access to palliative care by disease trajectory: a
424 population-based cohort of Ontario decedents. *BMJ Open*. 2018 Apr 1;8(4):e021147.

- 425 41. Quinn KL, Stukel TA, Campos E, Graham C, Kavalieratos D, Mak S, et al. Regional collaborative home-
426 based palliative care and health care outcomes among adults with heart failure. *CMAJ Can Med*
427 *Assoc J*. 2022 Sep 26;194(37):E1274–82.
- 428 42. Webber C. Delivery of Palliative Care in Acute Care Hospitals: A Population-Based Retrospective
429 Cohort Study Describing the Level of Involvement and Timing of Inpatient Palliative Care in the Last
430 Year of Life | *Journal of Palliative Medicine*. [cited 2024 Jun 3]; Available from: [https://www-
431 liebertpub-com.proxy.library.vcu.edu/doi/10.1089/jpm.2020.0056?url_ver=Z39.88-
432 2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed](https://www-liebertpub-com.proxy.library.vcu.edu/doi/10.1089/jpm.2020.0056?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
- 433 43. Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, et al. Palliative care use amongst
434 patients with bladder cancer. *BJU Int*. 2019 Jun;123(6):968–75.
- 435 44. Hua M, Guo L, Ing C, Lackraj D, Wang S, Morrison RS. Specialist Palliative Care Use and End-of-Life
436 Care in Patients With Metastatic Cancer. *J Pain Symptom Manage*. 2024 May 1;67(5):357-365.e15.
- 437 45. Scibetta C, Kerr K, Mcguire J, Rabow MW. The Costs of Waiting: Implications of the Timing of
438 Palliative Care Consultation among a Cohort of Decedents at a Comprehensive Cancer Center. *J*
439 *Palliat Med*. 2016 Jan;19(1):69–75.
- 440 46. Hui D, Kim SH, Roquemore J, Dev R, Chisholm G, Bruera E. Impact of timing and setting of palliative
441 care referral on quality of end-of-life care in cancer patients. *Cancer*. 2014;120(11):1743–9.
- 442 47. Cassel JB, Kerr KM, McClish DK, Skoro N, Johnson S, Wanke C, et al. Effect of a Home-Based
443 Palliative Care Program on Healthcare Use and Costs. *J Am Geriatr Soc*. 2016;64(11):2288–95.
- 444
- 445